semaspace semaglutide (closed) Reviews Semaspace Closed What Replaced It

Individuals with the following conditions may be at heightened risk and should be assessed carefully: Pre-existing arrhythmias , including atrial fibrillation or supraventricular tachycardia, given the drug's association with elevated resting heart rate Heart failure , particularly where heart rate control is a key management goal Ischaemic heart disease , where any increase in myocardial oxygen demand could be clinically significant Uncontrolled hypertension , although retatrutide may itself reduce blood pressure over time Patients on rate-modifying medications such as beta-blockers or calcium channel blockers whilst no direct pharmacokinetic drugdrug interactions have been established, the heart rate effects of retatrutide may complicate clinical management and require closer monitoring Patients with a recent acute coronary syndrome, decompensated heart failure, or unstable angina are typically excluded from clinical trials of this class of agent

Baseline weight was taken in AEMR between 90 days pre index to 30 days post index, using the value closest to the actual index date

(3) a control of a placebo group

The Science of Safety: Adverse Effects of GLP-1 Receptor Agonists as Glucose-Lowering and Obesity Medications

[DOI] [PMC free article] [PubMed] [Google Scholar] 7.Sohal A, Casanova L, Kowdley KV